Want to join the conversation?
$CELG 2Q15 Call: Total net product sales grew 22% to approximately $2.25Bil. The growth was driven by strong performances by REVLIMID and POMALYST/IMNOVID. ABRAXANE continues to grow nicely in pancreatic cancer & OTEZLA’s launch remains on track, achieving the desired pre-biologic positioning, strong adoption & is well positioned for future success
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.